Chemical: Drug
gentamicin

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for gentamicin

Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Alcomicin
  • Apogen
  • Bristagen
  • G-Mycin
  • G-Myticin
  • Garamycin
  • Garamycin Otic Solution
  • Genoptic Liquifilm
  • Genoptic S.O.P.
  • Gentacidin
  • Gentafair
  • Gentak
  • Gentamar
  • Gentamcin Sulfate
  • Jenamicin
  • Ocu-Mycin
  • Spectro-Genta
  • U-gencin
Brand Mixture Names
  • Diprogen Crm (Betamethasone Dipropionate + Gentamicin Sulfate)
  • Diprogen Ont (Betamethasone Dipropionate + Gentamicin Sulfate)
  • Garasone Oph/Ot Sol (Betamethasone + Gentamicin Sulfate)
  • Garasone Ophthalmic Ointment (Betamethasone + Gentamicin Sulfate)
  • Gentamicin Sulfate in Nacl 0.9% Inj (Gentamicin Sulfate + Sodium Chloride)
  • Gentocin Durafilm (Betamethasone 21-Acetate + Gentamicin Sulfate)
  • Gentocin Otic Solution (Betamethasone + Gentamicin Sulfate)
  • Otomax Ointment (Betamethasone + Clotrimazole + Gentamicin Sulfate)
  • Sandoz Pentasone (Betamethasone + Gentamicin Sulfate)
  • Topagen Ont (Betamethasone + Gentamicin Sulfate)
  • Topagen Spray (Betamethasone + Gentamicin Sulfate)
  • Valisone G Cream (Betamethasone + Gentamicin Sulfate)
  • Valisone G Ointment (Betamethasone + Gentamicin Sulfate)

PharmGKB Accession Id

PA449753

Type(s):

Drug

Description

A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation).

Source: Drug Bank

Indication

For treatment of serious infections caused by susceptible strains of the following microorganisms: _P. aeruginosa_, _Proteus_ species (indole-positive and indole-negative), _E. coli_, _Klebsiella-Enterobactor-Serratia_ species, _Citrobacter_ species and _Staphylococcus_ species (coagulase-positive and coagulase-negative).

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Aminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

Source: Drug Bank

Pharmacology

Gentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

Low (between 0 and 30%)

Source: Drug Bank

Absorption

Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). Gentamicin is very poorly absorbed orally.

Source: Drug Bank

Half-Life

3-3½ hours in infants one week to six months of age; this increases to 5½ hours in full-term and large premature infants less than one week old.

Source: Drug Bank

Toxicity

Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Gentamicin accumulates in proximal renal tubular cells and causes cell damage. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance. Mouse, intravenous LD50: 52 mg/kg; rat, intravenous LD50: 96 mg/kg.

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H43N5O7

Source: Drug Bank

Average Molecular Weight

477.5954

Source: Drug Bank

Monoisotopic Molecular Weight

477.316248755

Source: Drug Bank

SMILES

CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC

Source: PubChem

InChI String

InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3

Source: PubChem

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
MT-RNR1

Drug Targets

Gene Description
LRP2 (source: Drug Bank )

Drug Interactions

Interaction Description
bumetanide - gentamicin Increased ototoxicity (source: Drug Bank )
bumetanide - gentamicin Increased ototoxicity (source: Drug Bank )
cefotaxime - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
cefotaxime - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
cefotetan - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - gentamicin Increased risk of nephrotoxicity (source: Drug Bank )
ethacrynic acid - gentamicin Increased ototoxicity (source: Drug Bank )
ethacrynic acid - gentamicin Increased ototoxicity (source: Drug Bank )
furosemide - gentamicin Increased ototoxicity (source: Drug Bank )
furosemide - gentamicin Increased ototoxicity (source: Drug Bank )
gentamicin - atracurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - atracurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - bumetanide Increased ototoxicity (source: Drug Bank )
gentamicin - bumetanide Increased ototoxicity (source: Drug Bank )
gentamicin - cefalotin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefalotin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefamandole Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefamandole Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefazolin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefazolin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefonicid Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefonicid Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefoperazone Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefoperazone Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceforanide Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceforanide Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefotaxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefotaxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefotetan Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefotetan Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefoxitin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefoxitin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefradine Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefradine Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftazidime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftazidime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftizoxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftizoxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftriaxone Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - ceftriaxone Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefuroxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cefuroxime Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cephapirin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cephapirin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cisplatin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - cisplatin Increased risk of nephrotoxicity (source: Drug Bank )
gentamicin - doxacurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - doxacurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - ethacrynic acid Increased ototoxicity (source: Drug Bank )
gentamicin - furosemide Increased ototoxicity (source: Drug Bank )
gentamicin - furosemide Increased ototoxicity (source: Drug Bank )
gentamicin - gallamine triethiodide The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - gallamine triethiodide The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - metocurine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - metocurine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - mivacurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - mivacurium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - pancuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - pancuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - pipecuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - pipecuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - rocuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - rocuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - succinylcholine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - succinylcholine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - thalidomide Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank )
gentamicin - thalidomide Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank )
gentamicin - torasemide Increased ototoxicity (source: Drug Bank )
gentamicin - torasemide Increased ototoxicity (source: Drug Bank )
gentamicin - tubocurarine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - tubocurarine The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - vecuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
gentamicin - vecuronium The agent increases the effect of muscle relaxant (source: Drug Bank )
thalidomide - gentamicin Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank )
thalidomide - gentamicin Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank )
ticarcillin - gentamicin Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line. (source: Drug Bank )

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ototoxicity

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to gentamicin: 66

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of cystic fibrosis treatment. Pharmacogenomics. 2016. Carter Suzanne C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Allele-specific PCR for detecting the deafness-associated mitochondrial 12S rRNA mutations. Gene. 2016. Ding Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Is deafness mutation screening required in cystic fibrosis patients?. Paediatric respiratory reviews. 2016. Abusamra Rania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. British journal of clinical pharmacology. 2016. Bijleveld Yuma A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis. Journal of medical genetics. 2015. Jing Wu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Audio Profiles in Mitochondrial Deafness m.1555A>G and m.3243A>G Show Distinct Differences. Medical science monitor : international medical journal of experimental and clinical research. 2015. Iwanicka-Pronicka Katarzyna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic fibrosis: Toward personalized therapies. The international journal of biochemistry & cell biology. 2014. Ikpa Pauline T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?. International journal of pediatric otorhinolaryngology. 2014. Al-Malky Ghada, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. American journal of respiratory cell and molecular biology. 2014. Xue Xiaojiao, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. BMC pediatrics. 2014. Göpel Wolfgang, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Heteroplasmy levels of mtDNA1555A>G mutation is positively associated with diverse phenotypes and mutation transmission in a Chinese family. Biochemical and biophysical research communications. 2012. Shen Shan-Shan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo. The pharmacogenomics journal. 2011. Bolze F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Unique penetrance of hearing loss in a five-generation Chinese family with the mitochondrial 12S rRNA 1555A > G mutation. Acta oto-laryngologica. 2011. Men Meichao, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The prevalence of mitochondrial mutations associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. The Laryngoscope. 2011. Ealy Megan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Molecular epidemiological analysis of mitochondrial DNA12SrRNA A1555G, GJB2, and SLC26A4 mutations in sporadic outpatients with nonsyndromic sensorineural hearing loss in China. Acta oto-laryngologica. 2011. Ji Yu-bin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Detection of deafness-causing mutations in the Greek mitochondrial genome. Disease markers. 2011. Kokotas Haris, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion. 2010. Lu Jianxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic mutations and aminoglycoside-induced ototoxicity in neonates. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2010. Johnson Romaine F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochemical and biophysical research communications. 2010. Rydzanicz Małgorzata, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extensive and rapid screening for major mitochondrial DNA point mutations in patients with hereditary hearing loss. Journal of human genetics. 2010. Kato Tomofumi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial haplotypes may modulate the phenotypic manifestation of the deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion. 2010. Lu Jianxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial haplotype and phenotype of 13 Chinese families may suggest multi-original evolution of mitochondrial C1494T mutation. Mitochondrion. 2009. Zhu Yuhua, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial tRNA(Glu) A14693G variant may modulate the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in a Han Chinese family. Journal of genetics and genomics = Yi chuan xue bao. 2009. Ding Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation analysis of mitochondrial DNA 12SrRNA and tRNASer(UCN) genes in non-syndromic hearing loss patients. Mitochondrion. 2008. Konings Annelies, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenetics and genomics. 2008. Conrad Douglas J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial tRNAThr G15927A mutation may modulate the phenotypic manifestation of ototoxic 12S rRNA A1555G mutation in four Chinese families. Pharmacogenetics and genomics. 2008. Wang Xinjian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chemical research in toxicology. 2008. Xu Ethan Yixun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. Human mutation. 2008. Ballana Ester, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Whole mitochondrial genome screening in maternally inherited non-syndromic hearing impairment using a microarray resequencing mitochondrial DNA chip. European journal of human genetics : EJHG. 2007. Lévêque Marianne, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Coexistence of mitochondrial 12S rRNA C1494T and CO1/tRNA(Ser(UCN)) G7444A mutations in two Han Chinese pedigrees with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2007. Yuan Huijun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited aminoglycoside-induced and nonsyndromic hearing loss is associated with the 12S rRNA C1494T mutation in three Han Chinese pedigrees. Gene. 2007. Chen Jianfu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The mitochondrial tRNA(Ala) T5628C variant may have a modifying role in the phenotypic manifestation of the 12S rRNA C1494T mutation in a large Chinese family with hearing loss. Biochemical and biophysical research communications. 2007. Han Dongyi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Very low penetrance of hearing loss in seven Han Chinese pedigrees carrying the deafness-associated 12S rRNA A1555G mutation. Gene. 2007. Tang Xiaowen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Molecular and clinical characterisation of three Spanish families with maternally inherited non-syndromic hearing loss caused by the 1494C->T mutation in the mitochondrial 12S rRNA gene. Journal of medical genetics. 2006. Rodríguez-Ballesteros M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants in mitochondrial tRNAGlu, tRNAArg, and tRNAThr may influence the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in three Han Chinese families with hearing loss. American journal of medical genetics. Part A. 2006. Young Wie-Yen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA T1095C mutation in three Chinese families. Biochemical and biophysical research communications. 2006. Dai Pu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. Biochemical and biophysical research communications. 2006. Bravo Olga, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochemical and biophysical research communications. 2006. Ballana Ester, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical and molecular analysis of a four-generation Chinese family with aminoglycoside-induced and nonsyndromic hearing loss associated with the mitochondrial 12S rRNA C1494T mutation. Biochemical and biophysical research communications. 2006. Wang Qiuju, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: implication for early detection and prevention of deafness. Biochemical and biophysical research communications. 2006. Dai Pu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical evaluation and mitochondrial DNA sequence analysis in two Chinese families with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2005. Zhao Lidong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. Auris, nasus, larynx. 2005. Kobayashi Katsuhiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. Human genetics. 2005. Li Zhiyuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of hearing loss in four Chinese families with the mitochondrial 12S rRNA A1555G mutation. Biochemical and biophysical research communications. 2005. Young Wie-Yen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical evaluation and sequence analysis of the complete mitochondrial genome of three Chinese patients with hearing impairment associated with the 12S rRNA T1095C mutation. Biochemical and biophysical research communications. 2004. Zhao Lidong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Audiovestibular findings in patients with mitochondrial A1555G mutation. The Laryngoscope. 2004. Noguchi Yoshihiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. American journal of human genetics. 2004. Zhao Hui, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cosegregation of C-insertion at position 961 with the A1555G mutation of the mitochondrial 12S rRNA gene in a large Chinese family with maternally inherited hearing loss. American journal of medical genetics. Part A. 2004. Li Ronghua, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss. Journal of medical genetics. 2003. del Castillo F J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Atypical muscle pathology and a survey of cis-mutations in deaf patients harboring a 1555 A-to-G point mutation in the mitochondrial ribosomal RNA gene. Neuromuscular disorders : NMD. 2002. Yamasoba Tatsuya, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation A1555G in the 12S rRNA gene and its epidemiological importance in German, Hungarian, and Polish patients. Human mutation. 2002. Kupka Susan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited deafness associated with a T1095C mutation in the mDNA. European journal of human genetics : EJHG. 2001. Tessa A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Different clinical characteristics of aminoglycoside-induced profound deafness with and without the 1555 A-->G mitochondrial mutation. ORL; journal for oto-rhino-laryngology and its related specialties. 2001. Tono T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Annals of neurology. 2000. Thyagarajan D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prevalence of mitochondrial gene mutations among hearing impaired patients. Journal of medical genetics. 2000. Usami S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Aminoglycoside-induced deafness associated with the mitochondrial DNA mutation A1555G. American journal of otolaryngology. 1999. Shohat M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cochlear implantation in a patient with profound hearing loss with the A1555G mitochondrial mutation. The American journal of otology. 1998. Tono T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Hearing loss due to the mitochondrial A1555G mutation in Italian families. American journal of medical genetics. 1998. Casano R A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. American journal of human genetics. 1998. Estivill X, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Familial streptomycin ototoxicity in a South African family: a mitochondrial disorder. Journal of medical genetics. 1997. Gardner J C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. The Laryngoscope. 1997. Usami S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. Journal of medical genetics. 1997. Pandya A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. American journal of otolaryngology. 1997. Fischel-Ghodsian N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic acids research. 1993. Hutchin T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nature genetics. 1993. Prezant T R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. American journal of otolaryngology. 1993. Fischel-Ghodsian N, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
17478-283-10
DrugBank:
DB00798
ChEBI:
17833
KEGG Compound:
C00505
PubChem Compound:
3467
PubChem Substance:
3788
46506523
IUPHAR Ligand:
2427
Drugs Product Database (DPD):
776521
ChemSpider:
3348
Therapeutic Targets Database:
DAP000116
FDA Drug Label at DailyMed:
877ab1fd-6c0e-42f6-9522-f5efaa96018d

Clinical Trials

These are trials that mention gentamicin and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.